Diazepam: Clinical Overview
Diazepam is a benzodiazepine with multiple clinical applications including status epilepticus, procedural sedation, anxiety disorders, and muscle spasm, but its use requires careful attention to dosing, respiratory monitoring, and recognition that midazolam or lorazepam are often preferred alternatives in many acute settings.
Primary Clinical Indications
Status Epilepticus
For pediatric status epilepticus, administer IV diazepam 0.1-0.3 mg/kg every 5-10 minutes (maximum 10 mg per dose) over approximately 2 minutes 1. The rectal route (0.5 mg/kg up to 20 mg) may be used when IV access is unavailable, though absorption is erratic 1.
Critical limitation: Diazepam must be followed immediately by a long-acting anticonvulsant (phenytoin/fosphenytoin) because it redistributes rapidly and seizures often recur within 15-20 minutes 1. Lorazepam is generally preferred over diazepam for status epilepticus due to its prolonged duration of anticonvulsant activity 1.
For adults with refractory status epilepticus, guidelines support diazepam as part of the benzodiazepine class, though specific agent selection varies 2.
Procedural Sedation
For endoscopic procedures in adults, the initial dose is 5-10 mg IV over 1 minute, with additional doses at 5-minute intervals as needed 3. Generally 10 mg IV suffices for most procedures, though up to 20 mg may be necessary if no opioid is co-administered 3.
Important caveat: Midazolam has largely replaced diazepam for procedural sedation due to its faster onset (1-2 minutes vs. 2-5 minutes), shorter duration of effect (15-80 minutes vs. prolonged), and superior pharmacologic profile 3. Diazepam causes more phlebitis when administered through peripheral veins 4.
ICU Sedation
Diazepam is NOT recommended for routine ICU sedation 4. It has an extremely long elimination half-life (20-120 hours), active metabolites that accumulate especially in renal dysfunction, and causes prolonged sedation 4. The 2013 Critical Care Medicine guidelines list diazepam with a loading dose of 5-10 mg and maintenance of 0.03-0.1 mg/kg every 0.5-6 hours PRN, but note it causes respiratory depression, hypotension, and phlebitis 4.
Pharmacology
Mechanism
Diazepam enhances GABA-A receptor activity, producing anxiolysis, sedation, amnesia, anticonvulsant effects, and muscle relaxation—but no analgesic activity 3, 4.
Pharmacokinetics
- Onset: 2-5 minutes IV 4
- Elimination half-life: 20-120 hours 4
- Active metabolites: Yes—these prolong sedation, especially in renal failure 4
- Metabolism: Hepatic via cytochrome P450 4
The long half-life and active metabolites make diazepam unsuitable for situations requiring predictable, short-duration sedation 4.
Critical Safety Considerations
Respiratory Depression
The most serious adverse effect is dose-dependent respiratory depression, which results from depression of central ventilatory response to hypoxia and hypercapnea 3. Risk is dramatically increased when:
- Combined with opioids (synergistic effect) 1, 3
- Given rapidly IV 1
- Used in patients with underlying respiratory disease 3
Monitor oxygen saturation and respiratory effort continuously. Be prepared to support ventilation 1.
Cardiovascular Effects
Diazepam can cause hypotension, particularly in critically ill patients with baseline cardiovascular instability 4. This is more pronounced when combined with opioids 3.
Special Populations
- Elderly patients: Require dose reduction of 20% or more; significantly more sensitive to sedative effects 3, 4
- Hepatic dysfunction: Clearance is reduced; use with extreme caution 4
- Renal failure: Active metabolites accumulate, prolonging effects 4
- Pediatric: Contraindicated under 6 months of age 5
Contraindications
Absolute contraindications per FDA labeling 5:
- Known hypersensitivity
- Myasthenia gravis
- Severe respiratory insufficiency
- Severe hepatic insufficiency
- Sleep apnea syndrome
- Acute narrow-angle glaucoma
- Age <6 months
Reversal Agent
Flumazenil (0.01-0.02 mg/kg IV, maximum 0.2 mg) can reverse life-threatening respiratory depression 1. However, it also counteracts anticonvulsant effects and may precipitate seizures—use with extreme caution in seizure patients 1. Contraindicated in tricyclic antidepressant overdose 1.
Dosing Specifics by Indication
Anxiety (Outpatient)
Diazepam should be used in single doses, very short courses (1-7 days), or short courses (2-4 weeks)—rarely for longer-term treatment 6. The effective dose appears to be 12-18 mg/day for ≥2 weeks; 6 mg/day shows no significant difference from placebo 7. Diazepam is usually the drug of choice for episodic anxiety, acute stress reactions, and initial treatment of severe panic 6.
Tapering for Discontinuation
When discontinuing long-term benzodiazepines, use hyperbolic (proportionate) tapering rather than linear reductions 8. Linear reductions produce increasingly large changes in receptor occupancy, predicting escalating withdrawal effects. Final doses may need to be as small as 0.2 mg diazepam or less 8. Liquids or compounded formulations help make small reductions at low doses 8.
Practical Pitfalls
IM route NOT recommended for status epilepticus—causes tissue necrosis; use lorazepam or midazolam IM instead 1
Rapid IV push causes pain at injection site—administer over ~2 minutes 1
Paradoxical excitement or agitation can occur 1
Physical dependence occurs even with prescribed use—distinct from addiction 9, 8
When to Choose Alternatives
Midazolam is preferred over diazepam for:
- Procedural sedation (faster onset, shorter duration, less phlebitis) 3
- IM administration (diazepam causes tissue necrosis) 1
Lorazepam is preferred over diazepam for:
- Status epilepticus (longer anticonvulsant duration) 1
- Situations requiring predictable duration of effect 4
Avoid diazepam entirely for: